Viatris Inc
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
About Viatris
Pharmaceutical Preparations, SIC 2834
Viatris Inc. is a global healthcare company that provides pharmaceutical treatments across more than ten major therapeutic categories, including cardiovascular health, oncology, and infectious diseases. Its portfolio comprises generic medications, complex formulations, established iconic brands, and innovative therapies. The company operates through four commercial segments: Developed Markets, Emerging Markets, JANZ, and Greater China. Its primary customers include retail and pharmacy establishments, pharmaceutical wholesalers and distributors, governments, insurers, and healthcare institutions like hospitals.
The company delivers medicines across more than 165 countries and territories, reaching approximately one billion patients annually. Its operational network features 27 manufacturing, packaging, and distribution facilities across five continents, supported by more than 30,000 employees worldwide. Viatris is headquartered in the United States, with global centers located in Pittsburgh, Pennsylvania; Shanghai, China; and Hyderabad, India.
Summary of the business section of Viatris's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Viatris Inc
- Founded
- 1961
- Headquarters
- Canonsburg, PA
- Address
- 1000 Mylan Boulevard 15317
- Phone
- (724) 514-1465
- Website
- www.viatris.com
- Employees
- 30,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- DELOITTE & TOUCHE LLP, Pittsburgh, Pennsylvania
Stock & identifiers
- Ticker
- VTRS
- Exchange
- Nasdaq
- Shares outstanding
- 1.15B, Aug 3, 2026
- Public float
- $10.38B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-2, Oct 9, 2003; 3-for-2, Jan 28, 2003; 3-for-2, Aug 16, 1995; 2-for-1, Aug 3, 1992
- SEC CIK
- 1792044
- CUSIP
- 92556V106
- ISIN
- US92556V1061
- LEI
- 254900ZZTSW7NL773X71
- EIN
- 83-4364296
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Scott Andrew Smith | Chief Executive Officer, Director | 1,374,576 |
| Andrew Enrietti | See Remarks | 233,880 |
| Paul Campbell | See Remarks | 316,530 |
| Goff Corinne Le | Chief Commercial Officer | 108,752 |
| Theodora Mistras | Chief Financial Officer | 92,787 |
| Matthew Joseph Maletta | Chief Legal Officer | 25 |
| Brian Roman | Chief Legal Officer | 112,267 |
| Leo Frans Groothuis | Director | 63,437 |
| David S. Simmons | Director | 24,003 |
| Richard A. Mark | Director | 114,970 |
| Melina E. Higgins | Director | 220,048 |
| Frank A. Damelio | Director | 26,031 |
| Elisha W. Finney | Director | 61,492 |
| W. Don Cornwell | Director | 112,044 |
| James M. Kilts | Director | 161,257 |
| Mark W. Parrish | Director | 165,230 |
| Michael Severino | Director | 26,031 |
| Coelho Rogerio Vivaldi | Director | 45,351 |
| Dillon JoEllen Lyons | Director | 102,544 |
| Harry Korman | Director | 113,164 |
| Rajiv Malik | Director | 627,574 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael Goettler | $0 | $0 | $5.15M | $81 | $186 |
| FY2025 Scott ASmith | $15.27M | $24.70M | $5.15M | $81 | $186 |
| FY2024 Michael Goettler | $0 | $0 | $5.55M | $77 | $145 |
| FY2024 Scott ASmith | $14.76M | $17.79M | $5.55M | $77 | $145 |
| FY2023 Michael Goettler | $9.84M | -$4.92M | $14.26M | $65 | $135 |
| FY2023 Scott A | $15.93M | $17.79M | $14.26M | $65 | $135 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 3, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 1, 2022 | Tender offer | Third-party tender offer for the company's shares |
| Nov 29, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 10, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Nov 25, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 19, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 10, 2020 | Name change | Name changed from Upjohn Inc to Viatris Inc |
| Nov 10, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Oct 25, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |